



HAL
open science

O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)

Annie Lemelin, Marc Barritault, Valérie Hervieu, Léa Payen, Julien Péron, Anne Couvelard, Jérôme Cros, Jean-Yves Scoazec, Sylvie Bin, Laurent Villeneuve, et al.

► To cite this version:

Annie Lemelin, Marc Barritault, Valérie Hervieu, Léa Payen, Julien Péron, et al.. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET). *Digestive and Liver Disease*, 2019, 51, pp.595 - 599. 10.1016/j.dld.2019.02.001 . hal-03486315

HAL Id: hal-03486315

<https://hal.science/hal-03486315>

Submitted on 21 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

TITLE PAGE

Progress Report in *Dig Liv Dis* - **DLD-18-1117**

Title: O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)

Authors:

Annie Lemelin¹, Marc Barrिताult², Valérie Hervieu³, Léa Payen⁴, Julien Péron⁵, Anne Couvelard⁶, Jérôme Cros⁷, Jean-Yves Scoazec⁸, Sylvie Bin⁹, Laurent Villeneuve⁹, Catherine Lombard-Bohas¹, Thomas Walter¹, for the MGMT-NET investigators/collaborators#

#Please see the Supplementary Appendix for a list of the MGMT-NET Investigators/Collaborators

¹Department of Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France

²Departement of Molecular Biology, Institute of Multi-Site Pathology of the HCL-Est Site, GHE University Hospital, Bron, France

³Institute of Multi-Site Pathology of the HCL-Est Site, GHE University Hospital, Bron, France

⁴CIRCAN (CIRculating CANcer) Platform, GHS University Hospital, Pierre-Benite, France

⁵Department of Biostatistics, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon

⁶Department of Pathology, Bichat Hospital, Paris, France

⁷Department of Pathology, Beaujon University Hospital, Clichy, France

⁸Gustave Roussy Cancer Campus, Department of Surgical and Molecular Pathology, Villejuif, France

⁹Pole Information Médical Recherche, Clinical Research Department, Lyon, France

Electronic word count: 2023

Corresponding Author:

Thomas Walter

Pavillon E, UJOMM, Hôpital Edouard Herriot, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL)

69437 Lyon Cedex 03, France

Fax number: +33 (0)4 72 11 96 91

Phone number: +33 (0)4 72 11 73 98

E-mail address: Thomas.walter@chu-lyon.fr

Source of support

Supported by Clinical Research Hospital Program grants (PHRC 2016) from the French ministry of health (PHRCK-16-0208).

Abstract

Introduction: Neuroendocrine tumors (NETs) are rare, but their incidence is rising. Alkylating agents (ALKY), temozolomide and streptozotocin, are the main chemotherapies used for advanced pancreatic NETs. According to retrospective data, O6-methylguanine-DNA methyltransferase (MGMT) status appears to be a predictive factor of the response to ALKY.

Aims: The main objective is to evaluate the value of tumor *MGMT* promoter (*pMGMT*) methylation in the prediction of the objective response (OR) at 3 months in patients treated with ALKY. Secondly, we will evaluate the value of MGMT immunohistochemistry and the efficacy of treatment with ALKY vs. oxaliplatin-based chemotherapy (Ox).

Materials and methods: A national, prospective, open-label, randomized, controlled and multicenter trial was designed. Main inclusion criteria are: adult patients with well-differentiated advanced duodeno-pancreatic, lung, or unknown primitive NETs with a validated indication for chemotherapy. *pMGMT* methylation will be assessed by pyrosequencing, but an ancillary study will compare this technique with others ones including MGMT immunohistochemistry.

Results: A total of 104 patients will be randomly assigned (1:1 for unmethylated or 2:1 for methylated *pMGMT* NETs) to either the ALKY arm or to the Ox arm.

Conclusion: Recruitment started on October 16, 2018 (NCT03217097) and will be open in 21 centers in France.

Keywords: Neuroendocrine; Clinical trial; O6-Methylguanine-DNA methyltransferase; Alkylating agents

1. Rational and aims

Neuroendocrine tumors (NET) are rare, but their incidence is rising and their prevalence is high (1). Most occur in the digestive system (68%) and the bronchopulmonary system (25%), and more than 60% are diagnosed at advanced, unresectable stages (1). Chemotherapy is one of the few therapeutic weapons, along with targeted therapies, somatostatin analogs, and metabolic radiotherapy. Alkylating agents (ALKY), temozolomide and streptozotocin, are one of the main systemic treatments used (2-4), at least for advanced duodeno-pancreatic NETs; the response rate is 30% to 40% and the median progression-free survival is 4 to 18 months (2, 5-9). However, it should be noted that for pulmonary NETs, called typical and atypical carcinoids, the level of proof of efficacy of these treatments is lower than for duodeno-pancreatic NETs.

One of the mechanisms of ALKY cytotoxicity is the induction of DNA alkylation/methylation at O6-guanine sites, resulting in DNA mismatch and cell death in tumor tissue (10). However, ALKY-induced DNA damage can be repaired by O6-Methylguanine-DNA methyltransferase (MGMT). Any reduction in MGMT activity may therefore potentiate the effect of ALKY. The expression of MGMT has been shown to be decreased in some tumor cells, mainly as a result of gene promoter hypermethylation (11). Thus, MGMT status has been proposed as a predictive factor for the response to ALKY; it can be assessed at the protein level (by immunohistochemistry, IHC) and at the gene level (through methylation analysis). The current literature is conflicted as to the value of MGMT to predict response to ALKY, in part because MGMT status is assessed by multiple techniques with various accuracy, but also because of the retrospective nature of the studies reported and the low number of patients included (12-21) (Table 1).

In glioblastoma, methylation of *pMGMT* is predictive of the efficacy of temozolomide with an increased survival (22-25). As in glioblastoma (24, 26-28), *pMGMT* methylation assessed by

pyrosequencing (with immunochemistry, IHC) is the most effective and reproducible technique to predict the response to ALKY in NETs (13). *pMGMT* is methylated in 25%-50% of NETs in general, but it should be noted that a variation exists depending on the site of primitive cancer. Current data estimate a methylation of *pMGMT* in about 50% of pancreatic NETs and 0%-15% of lung and gastro-intestinal NETs (12, 13, 17). This variation could also contribute to the different chemosensitivities of these tumors. To the best of our knowledge no prospective study investigating MGMT status in NET has been published; currently, two studies are registered in ClinicalTrials.gov that evaluates MGMT as a secondary endpoint (NCT02698410 and NCT01824875). The latter was recently presented by Kunz *et al.* at the ASCO 2018 annual meeting, but results regarding MGMT are currently pending (9).

Furthermore, although ALKY are commonly recommended upfront in NET (2-4), oxaliplatin (Ox), either with 5-fluorouracile (29-35) or with gemcitabine (33, 36), has shown interesting activity with response rates ranging from 17% to 30%. In a retrospective study, we demonstrated that GEMOX is effective in NET and that its activity is similar to ALKY, but irrespective of the MGMT status (16). Prospective studies are needed, but the data suggests that ALKY should be offered first to patients with *pMGMT* methylation while Ox-based chemotherapy should be offered first to patients with unmethylated *pMGMT* tumors.

In this context, the purpose of this prospective study is to evaluate the contribution of the *pMGMT* methylation, in predicting the objective response (OR) in patients treated with ALKY and to evaluate a treatment with ALKY versus Ox in patients with a NET.

2. Study design

The MGMT-NET study is a national, prospective, open-label, randomized, controlled and multicenter trial assessing the value of using the MGMT status in clinical practice to predict OR of patients suffering from NET. Patients included will first undergo analysis to determine

the MGMT status before randomization. Patients with unmethylated *pMGMT* NETs will be randomly assigned (1:1) to either the ALKY-based chemotherapy arm or to the Ox-based chemotherapy arm. Patients with methylated *pMGMT* NETs will be randomly assigned (2:1) to either the ALKY-based chemotherapy arm or to the Ox-based chemotherapy arm (Figure 1). As current data suggests that patients with methylated *pMGMT* respond better to ALKY (12, 13) we considered that a 1:1 randomization would not have been ethical for such patients. In addition, an Ox arm was included to facilitate recruitment by offering another option of treatment to patients. However, we considered that a phase III study designed to evaluate the best chemotherapy (Ox vs. ALKY) according to MGMT status in each arm would have been impossible to complete given the high number of patients needed and the rarity of the disease. This study includes patients aged 18 years or above, with a well-differentiated NET (duodeno-pancreatic, lung, or unknown primary site), grades 1 to 3, metastatic or locally advanced, and not curatively operable. Systemic chemotherapy must be indicated and validated by a multidisciplinary tumor board. Previous local or systemic treatments other than ALKY or Ox -based chemotherapy are allowed. Tumor tissue should be available for the patient to be included in order to investigate MGMT status. The main exclusion criteria are: previous chemotherapy using Ox or ALKY, and contraindication to any ALKY drugs or oxaliplatin. All patients must have given their written consent for participation in this trial. Methylation tests and IHC will be centralized and conducted on the most recent available histological material. *pMGMT*_methylation status will be evaluated using two techniques: methylation-specific polymerase chain reaction (MS-PCR) and pyrosequencing, which will provide, respectively, qualitative and quantitative information. The techniques used are derived from the procedures employed in our institution for gliomas. All examined samples must contain more than 80% tumor cells. DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue is performed after deparaffinization using a purification kit

(Promega, Madison, WI, USA, ref AS1450). Genomic DNA is modified by bisulfite conversion (EZ DNA Methylation Gold Kit, Zymo, Irvine, CA, US). For MS-PCR, we use the primers described by Dong *et al.* (37). For pyrosequencing analysis, an 8% cutoff is used (26). *pMGMT* promoter is therefore scored “methylated” if more than 8% methylated alleles are detected compared to unmethylated alleles. The results are presented as methylated, not methylated, or not interpretable. The MGMT protein expression will be evaluated by an immunohistochemical technique for which an automated immunostaining system will be used (Ventana Benchmark, Tucson, AZ, US). MGMT expression will be assessed on a whole slide using a score based on nuclear staining intensity (0-3) multiplied by the proportion of stained cells (0-100%). The score ranges from 0 to 300 and tumors are considered MGMT negative (loss of expression) if the score is ≤ 50 (17). *pMGMT* methylation test and IHC will be carried out in parallel, but only the result of the methylation test will be considered for randomization unless the result is not interpretable; in which case the IHC result will be used, considering that a loss of MGMT expression in IHC corresponds to a methylated *pMGMT*. If the *pMGMT* methylation test and the IHC result are both not interpretable, the patients will be randomized (ratio 1:1 between the two arms), but these patients will not be included in the analysis of the main outcome. Furthermore, a blood sample will be collected specifically for circulating free DNA (cfDNA) analyses.

Taking a pragmatic approach with a view to complete the study and because chemotherapy regimens in NETs are not standardized, we do not impose a specific regimen in both arms. However, one regimen in each arm is recommended in order to reduce heterogeneity: the ALKY-based chemotherapy arm will receive capecitabine (750 mg/m² twice daily for 14 days, days 1-14) and temozolomide (temozolomide, 200 mg/m² once daily for 5 days, days 10-14), every 28 days) (3, 9), alternatively LV5FU2-dacarbazine (for patients with expected difficulties with adherence to oral chemotherapy) or 5FU-streptozotocine (only approved in

France for pancreatic NET, therefore only used in this study in this situation). The recommended regimen in Ox-based chemotherapy arm is GEMOX (gemcitabine 1000 mg/m² followed by oxaliplatin 100 mg/m² every 2 weeks) (16); alternatively FOLFOX or CAPOX. Doses and monitoring of chemotherapies will be administered in accordance to French recommendations (38). The duration of chemotherapy recommended is at least 3 months (assessment of the primary endpoint), but physicians are allowed to continue chemotherapy, and do so usually for 4-12 months (2, 5-9).

The radiological assessment will be performed at baseline (within a maximum of 4 weeks before inclusion) using a computed tomography (CT) scan and/or magnetic resonance imaging (MRI), and the same procedure (CT or MRI) will be repeated at 3 months after the beginning of treatment to enable radiological tumor assessment according to the RECIST v1.1 criteria.

2.1 Study endpoints

The primary endpoint is the 3-month OR rate (complete response – CR, or partial response – PR) assessed according to the RECIST v1.1 criteria and based on a centralized reviewing performed by an expert radiologist blinded to the result of *pMGMT* methylation and treatment assignment.

The secondary endpoints are to evaluate and compare the progression-free survival (PFS) assessed by RECIST v1.1 criteria and overall survival (OS) according to *pMGMT* methylation in patients treated with ALKY; the OR at 3 months, PFS, and OS according to *pMGMT* methylation in patients treated with Ox-based chemotherapy; and to evaluate the value of the MGMT status for predicting OR at 3 months as assessed by RECIST v1.1 criteria based on MGMT status evaluated using immunochemistry. In addition, we will evaluate in tumor tissue and in cfDNA if possible, certain alterations previously described in pancreatic or lung NET,

such as DAXX/ATRX, mTOR pathway (PTEN, TSC2), MEN1, ARID, SMAD, VHL (39); their prognostic value in NET as assessed by RECIST v1.1 criteria will be explored.

2.2 Ethical considerations

This study is sponsored by the Hospices Civils de Lyon and was authorized by the French medicines agency (*Agence Nationale de Sécurité du Médicament et des produits de santé*, ANSM) on June 27, 2018. It was submitted and approved (August 1, 2018) by the institutional review board (*Comité de protection des personnes*).

This trial is registered on the clinicaltrials.gov website (NCT03217097). The study complies with the Declaration of Helsinki and the principles of Good Clinical Practice guidelines.

2.3 Statistical methods

The primary endpoint is the OR rate at 3 months among patients treated with ALKY according to *pMGMT* methylation status. OR will be compared between the two groups using a Chi-square test. The response rate and the associated 95% confidence interval (CI) will be provided for each group. The sample size calculation was calibrated to detect a 35% absolute difference in the OR at 3 months according to *pMGMT* methylation among patients treated with ALKY. This translates into an improvement in OR that ranges from 15% in patients with unmethylated *pMGMT* NETs to 50% in patients with methylated *pMGMT* NETs. This calculation is based on an expected number of 55 patients treated with ALKY (i.e. 22 patients with a methylated *pMGMT* NETs and 33 patients with an unmethylated *pMGMT* NETs) to obtain a 75% power to show a statistically significant ORR difference with a one-sided α risk of 5%. Considering the hypothesis that a third of the patients will have a methylated *pMGMT* tumor, 99 patients need to be randomized in the study. However, assuming that 5% of the patients will not be assessable for *pMGMT*, we plan to include 104 patients for *pMGMT*

methylation, and 99 patients will be randomized. The randomization will be conducted according to *pMGMT* methylation and stratified by the location of NET. PFS and OS will be estimated using the Kaplan-Meier method according to MGMT status and NET location. The first patient was included on October 16, 2018.

Conflicts of Interests

None declared

Funding

The study is funded by the French National Cancer Institute (PHRCK- 16-0208).

Acknowledgements

We thank Philip Robinson (DRCI, Hospices Civils de Lyon) for help in manuscript preparation.

Legend of Figure

Legend of figure 1: Study design. The methylation test and the IHC are carried out in parallel, but only the result of the methylation test is considered unless the result is not interpretable, in which case the IHC result will be used.

References

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26(18):3063-72.
2. Delaunoy T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, et al. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? *European journal of cancer (Oxford, England : 1990)*. 2004;40(4):515-20.
3. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. *Cancer*. 2011;117(2):268-75.
4. Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. *Clinical colorectal cancer*. 2010;9(4):248-54.
5. Auernhammer CJ, Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. *Gut*. 2011;60(7):1009-21.
6. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas*. 2010;39(6):735-52.
7. Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G. New treatment strategies in advanced neuroendocrine tumours. *Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*. 2012;44(2):95-105.
8. Weatherstone K, Meyer T. Streptozocin-based chemotherapy is not history in neuroendocrine tumours. *Targeted oncology*. 2012;7(3):161-8.
9. Kunz P. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group *J Clin Oncol* 36. 2018:(suppl; abstr 4004).
10. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. *Nature reviews Cancer*. 2004;4(4):296-307.
11. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. *Biochimica et biophysica acta*. 2011;1816(2):179-90.
12. Kulke MH, Hornick JL, Fraumeni C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2009;15(1):338-45.
13. Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. *British journal of cancer*. 2015;112(3):523-31.
14. Schmitt AM, Pavel M, Rudolph T, Dawson H, Blank A, Komminoth P, et al. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms. *Neuroendocrinology*. 2014;100(1):35-44.
15. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2007;13(10):2986-91.
16. Dussol AS, Joly MO, Vercherat C, Forestier J, Hervieu V, Scoazec JY, et al. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice. *Cancer*. 2015;121(19):3428-34.

17. Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. *Endocrine-related cancer*. 2016;23(8):625-33.
18. Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. *Endocrine-related cancer*. 2016;23(9):759-67.
19. Campana D, Walter T, Pusceddu S, Gelsomino F, Graillot E, Prinzi N, et al. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. *Endocrine*. 2018;60(3):490-8.
20. Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, et al. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. *Pancreas*. 2017;46(6):758-63.
21. Girot P, Dumars C, Mosnier JF, Muzellec L, Senellart H, Foubert F, et al. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. *European journal of gastroenterology & hepatology*. 2017;29(7):826-30.
22. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing--the challenges for biomarker-based glioma treatment. *Nature reviews Neurology*. 2014;10(7):372-85.
23. Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, et al. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. *British journal of cancer*. 1998;78(9):1199-202.
24. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *The New England journal of medicine*. 2005;352(10):997-1003.
25. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25(12):1470-5.
26. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. *Cancer*. 2012;118(17):4201-11.
27. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. *Journal of neuro-oncology*. 2010;97(3):311-22.
28. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nature reviews Neurology*. 2010;6(1):39-51.
29. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? *Cancer chemotherapy and pharmacology*. 2007;59(5):637-42.
30. A. P. Venook AHK, M. A. Tempero, J. Uy, T. Weber, M. Korn, and E. K. Bergsland. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. *Journal of Clinical Oncology*. 2008; 26:15_suppl, 15545-.
31. Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, et al. Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. *Rare tumors*. 2013;5(3):e35.

32. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, et al. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. *Pancreas*. 2016;45(10):1394-400.
33. Walter T, Planchard D, Bouledrak K, Scoazec JY, Souquet PJ, Dussol AS, et al. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. *Lung cancer (Amsterdam, Netherlands)*. 2016;96:68-73.
34. P. L. Kunz TK, J. M. Zahn, H. L. Kaiser, J. A. Norton, B. C. Visser, T. A. Longacre, J. M. Ford, R. R. Balise, and G. A. Fisher. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. *Journal of Clinical Oncology* 2010;28:15_suppl, 4104-.
35. Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, et al. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. *Neuroendocrinology*. 2016;103(6):806-14.
36. Cassier PA, Walter T, Eymard B, Ardisson P, Perol M, Paillet C, et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience. *Cancer*. 2009;115(15):3392-9.
37. Dong SM, Lee EJ, Jeon ES, Park CK, Kim KM. Progressive methylation during the serrated neoplasia pathway of the colorectum. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.* 2005;18(2):170-8.
38. Cadiot G BE, Coriat R, Couvelard A, de Mestier L, Dromain C, Gaujoux S, Gincul R, Lepage C, Lombard-Bohas C, Poncet G, Roquin G, Ruszniewski P, Smith D, Walter T. Tumeurs neuro-endocrines. *Thésaurus National de Cancérologie Digestive*. 12-10-2017.
39. Scarpa A, Chang DK, Nones K, Corbo V, Patch A-M, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*. 2017;543:65.

Supplementary Appendix for a list of the MGMT-NET Investigators/Collaborators

Hautefeuille V. Hepato-gastro-enterology Department, Amiens-Picardie University Hospital, Amiens, France

Roquin G. Hepato- Gastroenterology and Digestive cancer Department, Angers University Hospital, Angers, France

Baconnier M. Hepato-gastro-enterology Department, Annecy Genevois University Hospital, Annecy, France

Hentic O. Pancreato-Gastroenterology Department, Beaujon University Hospital, Clichy, France

Lepage C. Gastroenterology and Digestive cancer Department, François Mitterrand Hospital Dijon Bourgogne University Hospital, Dijon, France

Granger V. Hepato-Gastroenterology Department, André Michalon Hospital, Grenoble Alpes University Hospital

Do Cao C. Endocrinology and Diabetology Metabolism Department, Claude Hurriet Hospital, Lille Régional University Hospital, Lille, France

Dansin E. General Oncology Department, Anticancer Center Oscar Lambret, Lille, France

Sarabi M. Gastroenterology Department, Anticancer Center Léon Bérard, Lyon, France

Desrame J. Gastroenterology Department, Mermoz Hospital, Lyon, France

Niccoli P. Medical Oncology Department, Paoli-Calmettes Institute, Marseille, France

Assenat E. Medical oncology Department, Saint Eloi Hospital, Montpellier, France

Aparicio T. Hepato-Gastroenterology Department, AP-HP Saint Louis Hospital, Paris, France

Coriat, R Gastroenterology Department, AP-HP Cochin Hospital, Paris, France

Cadiot G. Hepato-Gastroenterology and Digestive cancerology Department, Robert Debré Hospital, Reims University Hospital, Reims, France

Williet N. Gastroenterology Department, North Hospital, Saint Etienne University Hospital ,
Saint-Priest-en-Jarez, France

Saban-Roche L. Medical Oncology Department, Cancer Institute of Loire, Saint-Priest-en-
Jarez, France

Guimbaud R. Medical Oncology Department, Ranguel Hospital, Toulouse University
Hospital, Toulouse, France

Lecomte T. Hepato-Gastro-Onco-Enterology Department, Trousseau Hospital, Tours
University Hospital, Tours, France

Baudin E. Medical Oncology Department ,Gustave Roussy Institute, Villejuif, France

Forestier J. Department of Medical Oncology, Edouard Herriot Hospital, Hospices Civils de
Lyon, Lyon, France

Garcia J. CIRCAN (CIRculating CANcer) Platform, GHS University Hospital, Pierre-Benite,
France

Robinson P. Hospices Civils de Lyon, DRCI, Lyon, France




Table 1. Main retrospective studies (n> 20 patients) in NETs evaluating response to alkylating agent-based chemotherapies according to the MGMT status.

	Number of treated patients	Best OR: MGMT deficient vs. not		PFS in months: MGMT deficient vs. not	
		MGMT status assessed by IHC	<i>p</i> MGMT methylation	MGMT status assessed by IHC	<i>p</i> MGMT methylation
Ekeblad 2007 (15)	23	40% vs. 8%	NA	NA	NA
Kulke 2009 (12)	21	80% vs. 0%*	NA	19 vs. 9*	NA
Walter 2015 (13)	69	62% vs. 7%*	50% vs. 11%*	20 vs. 8*	26 vs. 11*
Dussol 2015 (16)	26	38% vs. 9%	40% vs. 6%*	16 vs. 7	24 vs. 7*
Cros 2016 (17)	43	50% vs. 15%*	NA	23 vs. 11*	NR vs. 20*
Cives 2016 (18)	52	40% vs. 65%	NA	15 vs. 17	NA
Raj 2017 (20)	36	50% vs. 31%	25% vs. 38%	NA	NA
Giroto 2017 (21)	22	15% vs. 11%	0% vs. 17%	18 vs. 9	18 vs. 15
Campana 2018 (19)	95	NA	52% vs. 18%*	NA	21 vs. 8*

IHC, immunohistochemistry; NA, not available; NR, not reached; OR, objective response; PFS, progression-free survival

* p <0.05